title: Therapies on the Horizon for Diabetic Kidney Disease.
abstract: Diabetic nephropathy is rapidly becoming the major cause of end-stage renal disease and cardiovascular mortality worldwide. Standard of care therapies include strict glycemic control and blockade of the renin-angiotensin-aldosterone axis. While these treatments slow progression of diabetic nephropathy, they do not arrest or reverse it. Newer therapies targeting multiple molecular pathways involved in renal inflammation, fibrosis, and oxidative stress have shown promise in animal models. Subsequently, many of these agents have been investigated in clinical human trials with mixed results. In this review, we will discuss recent findings of novel agents used in the treatment of diabetic nephropathy.
authors.affiliation: Division of Nephrology and Hypertension, Feinberg School of Medicine, Northwestern University, 303 East Superior Lurie Building, 10th Floor, Chicago, IL, 60611, USA. sadaf.khan@northwestern.edu.
authors.forename: Sadaf S
authors.initials: SS
authors.lastname: Khan
authors.affiliation: Division of Nephrology and Hypertension, Feinberg School of Medicine, Northwestern University, 303 East Superior Lurie Building, 10th Floor, Chicago, IL, 60611, USA.
authors.forename: Susan E
authors.initials: SE
authors.lastname: Quaggin
mesh_terms: D000818:Animals; D003928:Diabetic Nephropathies / Q000378:metabolism / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D053612:Janus Kinases / Q000378:metabolism; D007676:Kidney Failure, Chronic; D018384:Oxidative Stress; D050791:STAT Transcription Factors / Q000378:metabolism; D015398:Signal Transduction; D016212:Transforming Growth Factor beta / Q000378:metabolism
chemical_list: D050791:STAT Transcription Factors; D016212:Transforming Growth Factor beta; D053612:Janus Kinases
keywords: Bardoxolone; Diabetic nephropathy; JAK/STAT; TGF-β